spectrum® PHARMACY PRODUCTS

800.370.6231
SpectrumRx.com

SUGGESTED FORMULA

Retinoic 0.1% Topical Gel
Version number: 1.0
Volume or quantity: 100 gm

Retinoic, USP (R1022)	0.1gm
Butylated Hydroxytoluene, NF (B1196)	0.4gm
Edetate Disodium Dihydrate, NF	0.1gm
Sodium Bisulfite	0.3gm
Propylene Glycol, USP (PR130)	10mL
Methylcellulose 3% Solution, Suspending agent	100mL

During the compounding of this formulation, use caution to not incorporate air into the preparation because air will increase the rate of oxidation and discoloration of the preparation. Also, package the preparation in containers to minimize headspace. An example would be to package in syringes so that, as the plunger is depressed and the amount of the preparation required is expelled for administration, there is no air space allowed in the syringe. Plastic tubes and ointment jars should not be used because they suck in air after delivering the medication or provide a surface area for air. This preparation should be prepared in a vertical airflow hood in a biological safety cabinet or barrier isolation technology.

SUGGESTED COMPOUNDING PROCEDURES

1. Calculate the required quantity of each ingredient for the total amount to be prepared
2. Accurately weight and/or measure each ingredient
3. Incorporate all the powders with the Propylene Glycol and mix well
4. Incorporate sufficient Methylcellulose 3% gel to volume and mix well
5. Package and Label
6. Suggested Quality assessments:
    a. color
    b. texture
    c. container
    d. Label - auxiliary labels, storage, BUD, compounded medication

Store in air-tight light resistant container
Room Temperature
For External use only

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates from reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date.
It is recommended that you follow USP <795> recommendations for potency testing.

Beyond-Use Date should be assigned according to the current USP <795> Standards

Precautions
Hazardous drugs should be handled according to USP <800>, NIOSH standards and pharmacy SOPs. This preparation should be compounded in a biological safety cabinet or compounding aseptic containment isolator. Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate personal protective equipment.

Although much attention has been paid to ensure the accuracy of the formulation contained here, Spectrum Pharmacy Products accepts no liability for the loss or damage arising from reliance on the information. Compounding pharmacists using this formula take full responsibility for the formulations and hold Spectrum Pharmacy Products and Spectrum Chemical Mfg Corp. and its officers, directors and employees harmless for any claim arising from use of or reliance on information contained therein.
02/20 JD

Phone: 800.370.6231 | Fax: 732.608.5420 | Internet: SpectrumRx.com | Email: sales@spectrumrx.com